CN112409410A - Application of silver catalyst in preparation of antibacterial intermediate - Google Patents
Application of silver catalyst in preparation of antibacterial intermediate Download PDFInfo
- Publication number
- CN112409410A CN112409410A CN202011426536.1A CN202011426536A CN112409410A CN 112409410 A CN112409410 A CN 112409410A CN 202011426536 A CN202011426536 A CN 202011426536A CN 112409410 A CN112409410 A CN 112409410A
- Authority
- CN
- China
- Prior art keywords
- fosfomycin
- silver catalyst
- salt
- levofosfomycin
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 39
- 239000003054 catalyst Substances 0.000 title claims abstract description 37
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 title claims abstract description 27
- 229910052709 silver Inorganic materials 0.000 title claims abstract description 27
- 239000004332 silver Substances 0.000 title claims abstract description 27
- 230000000844 anti-bacterial effect Effects 0.000 title claims description 18
- 229960000308 fosfomycin Drugs 0.000 claims abstract description 77
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 claims abstract description 67
- 150000003839 salts Chemical class 0.000 claims abstract description 58
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 54
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 40
- XWCIXXXLOAAWPU-IHWYPQMZSA-N [(z)-prop-1-enyl]phosphonic acid Chemical compound C\C=C/P(O)(O)=O XWCIXXXLOAAWPU-IHWYPQMZSA-N 0.000 claims abstract description 25
- 239000002904 solvent Substances 0.000 claims abstract description 20
- 238000003756 stirring Methods 0.000 claims abstract description 18
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 claims abstract description 15
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 claims abstract description 14
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 claims abstract description 14
- 229910001958 silver carbonate Inorganic materials 0.000 claims abstract description 14
- 229940124350 antibacterial drug Drugs 0.000 claims abstract description 11
- 238000006243 chemical reaction Methods 0.000 claims abstract description 11
- 238000001914 filtration Methods 0.000 claims abstract description 11
- 239000000706 filtrate Substances 0.000 claims abstract description 9
- 238000010438 heat treatment Methods 0.000 claims abstract description 7
- 238000005406 washing Methods 0.000 claims abstract description 7
- 238000001816 cooling Methods 0.000 claims abstract description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 230000003115 biocidal effect Effects 0.000 claims description 16
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 12
- 230000001476 alcoholic effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 11
- 230000003197 catalytic effect Effects 0.000 abstract description 5
- 238000004904 shortening Methods 0.000 abstract description 3
- 239000007800 oxidant agent Substances 0.000 abstract description 2
- 230000001590 oxidative effect Effects 0.000 abstract description 2
- 230000035484 reaction time Effects 0.000 abstract description 2
- 238000007243 oxidative cyclization reaction Methods 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 description 24
- 239000003814 drug Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 239000011574 phosphorus Substances 0.000 description 7
- 229910052698 phosphorus Inorganic materials 0.000 description 7
- 239000013078 crystal Substances 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000006735 epoxidation reaction Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 208000019206 urinary tract infection Diseases 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- QZIQJIKUVJMTDG-OTUWWBTESA-L disodium;[(2s,3r)-3-methyloxiran-2-yl]-dioxido-oxo-$l^{5}-phosphane Chemical compound [Na+].[Na+].C[C@H]1O[C@H]1P([O-])([O-])=O QZIQJIKUVJMTDG-OTUWWBTESA-L 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 208000013223 septicemia Diseases 0.000 description 2
- XMVONEAAOPAGAO-UHFFFAOYSA-N sodium tungstate Chemical compound [Na+].[Na+].[O-][W]([O-])(=O)=O XMVONEAAOPAGAO-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- UDPGUMQDCGORJQ-UHFFFAOYSA-N (2-chloroethyl)phosphonic acid Chemical compound OP(O)(=O)CCCl UDPGUMQDCGORJQ-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- 206010011844 Dacryocystitis Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010061977 Genital infection female Diseases 0.000 description 1
- 229910003893 H2WO4 Inorganic materials 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 206010056254 Intrauterine infection Diseases 0.000 description 1
- 229910020350 Na2WO4 Inorganic materials 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- KEINVACJRJKPCE-UHFFFAOYSA-N O=[W+2]=O Chemical compound O=[W+2]=O KEINVACJRJKPCE-UHFFFAOYSA-N 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 206010049677 Salpingo-oophoritis Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 206010061512 Serratia infection Diseases 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N activated carbon Substances [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- -1 amine salt Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000004690 coupled electron pair approximation Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000008025 hordeolum Diseases 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65502—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides an application of a silver catalyst in preparation of an antibacterial drug intermediate fosfomycin levo-fosfomycin dextroamine salt, which is characterized by comprising the following steps: at room temperature, dissolving cis-propenyl phosphonic acid in an alcohol solvent, slowly dripping (+) -alpha-phenylethylamine, adjusting the pH of the system to 5.5-6 after dripping is finished, continuously stirring for 1-3 min, then adding a silver catalyst, continuously and slowly dripping hydrogen peroxide, continuously stirring for 10-30 min after finishing dripping, quickly heating the system to 50-55 ℃, filtering while hot, cooling the filtrate, crystallizing and washing to obtain the fosfomycin levofosfomycin dextroamine salt. The invention takes silver carbonate as a catalyst and hydrogen peroxide as an oxidant, does not need to be heated in the process of oxidative cyclization, and can react at normal temperature. The silver carbonate has high catalytic activity, compared with the prior art, the method has the advantages of small dosage, mild reaction, effective shortening of reaction time, simple post-treatment and capability of separating the catalyst from the system only by filtering the system while the system is hot.
Description
Technical Field
The invention belongs to the field of drug synthesis, and particularly relates to a preparation method of an antibacterial drug intermediate, and more particularly relates to a preparation method of an important antibacterial drug intermediate fosfomycin levofosfomycin dextroamine salt.
Background
The chemical name of Fosfomycin (FOM) is (1R,2S- (-) -cis-1, 2-epoxypropylphosphonic acid, molecular formula is C3H7O4P is an antibiotic with broad spectrum, low toxicity, difficult sensitization and drug resistance and has synergistic effect with most antibiotics. Phosphomycin was produced in 1967 by the company CEPA of Spain and David and Spain in the United statesThe streptomyces in Spanish soil is found that fosfomycin has stable epoxy groups and phosphonic acid groups, has stable drug effect, has obvious synergistic effect with most similar drugs, is sensitive to staphylococcus, escherichia coli, meningococcus, gonococcus, typhoid bacillus, Serratia, proteus, pseudomonas aeruginosa, dysentery bacillus, helicobacter pylori and the like, can inhibit the synthesis of bacterial cell walls, is a bactericide in a breeding period, and has an inhibiting effect on most streptococcus, pseudomonas aeruginosa, proteus mirabilis and part of pneumonia bacillus and indole negative proteus. Fosfomycin is suitable for urinary tract infection, respiratory tract infection, digestive tract infection, gynecological infection, skin soft tissue infection and other parts infection and septicemia. The oral administration can treat intestinal infection, urinary tract infection, Serratia infection, helicobacter pylori infection, blepharitis, hordeolum, otitis media, paranasal sinusitis, dacryocystitis, etc.; the intravenous injection can be used for treating respiratory tract infection, urinary tract infection, septicemia, pelvic inflammatory disease, adnexitis, intrauterine infection and other gynecological diseases, and has wide application range. In addition, the fosfomycin can also improve the immunity of the organism, has moderate price and is popular with doctors and patients. The fosfomycin medicines include fosfomycin sodium, fosfomycin calcium, fosfomycin ammonia tributyl alcohol, etc.
The (1R,2S) - (-) -1, 2-epoxypropylphosphonic acid- (R) - (+) -alpha-phenylethylamine salt (abbreviated as fosfomycin levo-fosfomycin dextroamine salt or levofosfomycin dextroamine salt) is an important intermediate for synthesizing fosfomycin medicaments such as fosfomycin sodium, fosfomycin calcium, fosfomycin trometamol and the like.
At present, the main methods for synthesizing fosfomycin levofosfomycin dextroamine salt are as follows:
(1) propiolic alcohol is used as a raw material, cis-propenyl phosphonic acid is obtained through esterification, hydrolysis and hydrogenation, and then the cis-propenyl phosphonic acid and (+/-) alpha-phenylethylamine are salified in Na2WO4Obtaining 1, 2-epoxypropylphosphonic acid- (+/-) -alpha-phenylethylamine salt mixed salt through epoxidation reaction, and obtaining the levo-phosphamidoamine salt through splitting and recrystallization of the mixed salt. The method for synthesizing the fosfomycin levofosfomycin dextroamine salt has the advantages of long synthetic route, more side reactions, complex operation of particularly a racemic salt resolution process, high energy consumption, difficult mastering of a resolution technology and unstable product yield.
(2) The method is simple to operate, stable in product quality, capable of avoiding complex steps of splitting the racemic mixture, shortening the production flow, greatly improving the production efficiency, reducing the production cost and having good industrial value. However, sodium tungstate or sodium molybdate is used as a catalyst in the process, so that the recovery difficulty is high, the cost is high, sodium tungstate wastewater is usually directly discharged, the environment is polluted, and the resource waste is serious.
(3) The (R) - (+) -alpha-phenylethylamine and cis-propenyl phosphonic acid are used as raw materials, the chiral pyridinol dioxymolybdenum (VI) and tungsten (VI) dioxide complex are used as asymmetric epoxidation catalysts, the ee value of fosfomycin levo-phosphorus right amine salt is up to 78.0 percent, and the recovery rate of the chiral catalyst is 65 percent. However, the synthesis process of the chiral complex is complex, the conditions are harsh, and the yield is very low, so that the industrial production is difficult to realize.
(4) The chiral catalyst is used for catalyzing asymmetric epoxidation reaction of cis-propenyl phosphonic acid and (+/-) -alpha-phenylethylamine, the yield of the fosfomycin levo-phosphamidosalt is 64%, and the ee value is only 10.8%.
(5) H loaded with activated carbon2WO4the/C and the modified PW/C are used as catalysts for catalyzing the epoxidation reaction of the (+/-) -alpha-phenylethylamine salt of the cis-propenyl phosphonic acid, the yield of the mixed rotation salt of the modified PW/C catalyst is up to 84.6%, and the catalyst can be repeatedly used for 3-4 times. However, H2WO4The catalytic activity of the/C catalyst is low, the yield of the racemic salt is only about 60%, the preparation cost of the modified PW/C catalyst is high, the process is complex, and industrialization is difficult to realize.
Disclosure of Invention
The invention aims to overcome a series of defects existing in synthesis of fosfomycin levo-phosphorus dextroamine salt in the prior art, and provides a preparation method of fosfomycin levo-phosphorus dextroamine salt, which comprises the following steps: at room temperature, dissolving cis-propenyl phosphonic acid in an alcohol solvent, slowly dripping (+) -alpha-phenylethylamine, adjusting the pH of the system to 5.5-6 after dripping is finished, continuously stirring for 1-3 min, then adding a silver catalyst, continuously and slowly dripping hydrogen peroxide, continuously stirring for 10-30 min after finishing dripping, quickly heating the system to 50-55 ℃, filtering while hot, cooling the filtrate, crystallizing and washing to obtain the fosfomycin levofosfomycin dextroamine salt.
According to the preparation method of the antibiotic drug intermediate fosfomycin levo-fosfomycin dextroamine salt, the silver catalyst is preferably silver carbonate.
According to the preparation method of the antibiotic drug intermediate fosfomycin levo-fosfomycin dextroamine salt, the alcohol solvent is selected from one or more of methanol, ethanol, n-propanol or isopropanol.
According to the preparation method of the antibiotic drug intermediate fosfomycin levo-phosphorus dextroamine salt, the alcohol solvent is preferably ethanol. .
According to the preparation method of the antibacterial intermediate fosfomycin levophosphorus dextroamine salt, the feeding ratio of cis-propenyl phosphonic acid to the silver catalyst is 1mol: 1-5 g.
According to the preparation method of the antibacterial intermediate fosfomycin levo-phosphorus dextroamine salt, hydrogen peroxide is selected from hydrogen peroxide with the concentration of 30%, and the molar amount of the hydrogen peroxide is 1.5-2 times that of cis-propenyl phosphonic acid.
According to the preparation method of the antibiotic drug intermediate fosfomycin levo-fosfomycin dextroamine salt, a solvent used for washing is an alcohol solvent of ice.
According to the preparation method of the fosfomycin levofosfomycin dextroamine salt serving as the antibacterial drug intermediate, the alcohol solvent of ice is selected from one or more of ice methanol, ice ethanol, ice n-propanol or ice isopropanol.
According to the preparation method of the antibiotic intermediate fosfomycin levophosphorus dextroamine salt, the alcohol solvent of the ice is preferably the ethyl alcohol.
According to the preparation method of the antibacterial intermediate fosfomycin levo-fosfomycin dextroamine salt, the reaction system is cooled to 0-5 ℃.
According to the preparation method of the antibiotic intermediate fosfomycin levofosfomycin dextroamine salt, the rapid heating time to 50-55 ℃ is 1-3 min.
The preparation method of the antibiotic intermediate fosfomycin levofosfomycin dextroamine salt of the invention as claimed in the claim, wherein the molar charge ratio of the cis-propenyl phosphonic acid to the (+) -alpha-phenylethylamine is 1: 1-1.5.
According to the preparation method of fosfomycin levofosfomycin dextroamine salt as an antibacterial drug intermediate, the molar charge ratio of the cis-propenyl phosphonic acid to the (+) -alpha-phenylethylamine is preferably 1: 1.1-1.5.
The invention further provides application of the silver reagent in catalytic preparation of an antibacterial intermediate, preferably the silver reagent is silver carbonate, and further preferably the antibacterial intermediate is fosfomycin levofosfomycin dextroamine salt.
The main contributions of the present invention with respect to the prior art are the following:
(1) the invention takes silver carbonate as a catalyst and hydrogen peroxide as an oxidant, does not need to be heated in the oxidation cyclization process, can be reacted at normal temperature, and can obtain high yield only by a small amount of catalyst.
(2) The silver carbonate has high catalytic activity, compared with the prior art, the method has the advantages of small dosage, mild reaction, effective shortening of reaction time, simple post-treatment and capability of separating the catalyst from the system only by filtering the system while the system is hot.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present disclosure more apparent, the technical solutions of the embodiments of the present disclosure are clearly and completely described. It is to be understood that the described embodiments are only a few embodiments of the present disclosure, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the described embodiments of the disclosure without any inventive step, are within the scope of protection of the disclosure.
The invention provides a preparation method of fosfomycin levo-phosphamide, which comprises the following steps: at room temperature, dissolving cis-propenyl phosphonic acid in an alcohol solvent, slowly dripping (+) -alpha-phenylethylamine, adjusting the pH of the system to 5.5-6 after dripping is finished, continuously stirring for 1-3 min, then adding a silver catalyst, continuously and slowly dripping hydrogen peroxide, continuously stirring for 10-30 min after finishing dripping, quickly heating the system to 50-55 ℃, filtering while hot, cooling the filtrate, crystallizing and washing to obtain the fosfomycin levofosfomycin dextroamine salt.
According to the preparation method of the antibiotic drug intermediate fosfomycin levo-fosfomycin dextroamine salt, the silver catalyst is preferably silver carbonate.
According to the preparation method of the antibiotic drug intermediate fosfomycin levo-fosfomycin dextroamine salt, the alcohol solvent is selected from one or more of methanol, ethanol, n-propanol or isopropanol.
According to the preparation method of the antibiotic drug intermediate fosfomycin levo-phosphorus dextroamine salt, the alcohol solvent is preferably ethanol. .
According to the preparation method of the antibacterial intermediate fosfomycin levophosphorus dextroamine salt, the feeding ratio of cis-propenyl phosphonic acid to the silver catalyst is 1mol: 1-5 g.
According to the preparation method of the antibacterial intermediate fosfomycin levo-phosphorus dextroamine salt, hydrogen peroxide is selected from hydrogen peroxide with the concentration of 30%, and the molar amount of the hydrogen peroxide is 1.5-2 times that of cis-propenyl phosphonic acid.
According to the preparation method of the antibiotic drug intermediate fosfomycin levo-fosfomycin dextroamine salt, a solvent used for washing is an alcohol solvent of ice.
According to the preparation method of the fosfomycin levofosfomycin dextroamine salt serving as the antibacterial drug intermediate, the alcohol solvent of ice is selected from one or more of ice methanol, ice ethanol, ice n-propanol or ice isopropanol.
According to the preparation method of the antibiotic intermediate fosfomycin levophosphorus dextroamine salt, the alcohol solvent of the ice is preferably the ethyl alcohol.
According to the preparation method of the antibacterial intermediate fosfomycin levo-fosfomycin dextroamine salt, the reaction system is cooled to 0-5 ℃.
According to the preparation method of the antibiotic intermediate fosfomycin levofosfomycin dextroamine salt, the rapid heating time to 50-55 ℃ is 1-3 min.
The preparation method of the antibiotic intermediate fosfomycin levofosfomycin dextroamine salt of the invention as claimed in the claim, wherein the molar charge ratio of the cis-propenyl phosphonic acid to the (+) -alpha-phenylethylamine is 1: 1-1.5.
According to the preparation method of fosfomycin levofosfomycin dextroamine salt as an antibacterial drug intermediate, the molar charge ratio of the cis-propenyl phosphonic acid to the (+) -alpha-phenylethylamine is preferably 1: 1.1-1.5.
The invention further provides application of the silver reagent in catalytic preparation of an antibacterial intermediate, preferably the silver reagent is silver carbonate, and further preferably the antibacterial intermediate is fosfomycin levofosfomycin dextroamine salt.
Example 1
At room temperature, 0.1mol of cis-propenyl phosphonic acid is dissolved in absolute ethyl alcohol, then 0.11mol of (+) -alpha-phenylethylamine is slowly dripped, after the dripping is finished, the pH value of the system is adjusted to 5.5, the stirring is continued for 3min, then 0.2g of silver carbonate powder is added, 17g (0.15mol) of 30% hydrogen peroxide is slowly dripped, after the dripping is finished, the stirring is continued for 30min, the reaction is finished, then the system is heated to 55 ℃ within 3min, the hot filtering is carried out, the filtrate is cooled to 0 ℃ for crystallization, and then crystal is washed by using glacial ethyl alcohol to obtain the fosfomycin levofosfomycin dextroamine salt, wherein the yield is 94.6%.
Example 2
At room temperature, 0.1mol of cis-propenyl phosphonic acid is dissolved in absolute ethyl alcohol, then 0.15mol of (+) -alpha-phenylethylamine is slowly dripped, after the dripping is finished, the pH value of the system is adjusted to 6, the stirring is continuously carried out for 3min, then 0.5g of silver carbonate powder is added, 17g (0.15mol) of 30% hydrogen peroxide is slowly dripped, after the dripping is finished, the stirring is continuously carried out for 30min, the reaction is finished, then the system is heated to 60 ℃ within 3min, the hot filtering is carried out, the filtrate is cooled to 0 ℃ for crystallization, and then crystal is washed by using glacial ethanol to obtain the fosfomycin levofosfomycin dextroamine salt, wherein the yield is 96.2%.
Example 3
At room temperature, 0.1mol of cis-propenyl phosphonic acid is dissolved in absolute ethyl alcohol, then 0.11mol of (+) -alpha-phenylethylamine is slowly dripped, after the dripping is finished, the pH value of the system is adjusted to 6, the stirring is continuously carried out for 3min, then 0.1g of silver carbonate powder is added, 17g (0.15mol) of 30% hydrogen peroxide is slowly dripped, after the dripping is finished, the stirring is continuously carried out for 30min, the reaction is finished, then the system is heated to 60 ℃ within 3min, the hot filtering is carried out, the filtrate is cooled to 0 ℃ for crystallization, and then crystal is washed by using glacial ethanol to obtain the fosfomycin levofosfomycin dextroamine salt, wherein the yield is 93.8%.
Example 4
At room temperature, 0.1mol of cis-propenyl phosphonic acid is dissolved in anhydrous isopropanol, then 0.12mol of (+) -alpha-phenylethylamine is slowly dripped, after the dripping is finished, the pH value of the system is adjusted to 5.5, the stirring is continued for 3min, then 0.3g of silver carbonate powder is added, 17g (0.15mol) of 30% hydrogen peroxide is slowly dripped, after the dripping is finished, the stirring is continued for 30min, the reaction is finished, then the system is heated to 55 ℃ within 3min, the hot filtering is carried out, the filtrate is cooled to 0 ℃ for crystallization, and then the crystal is washed by using glacial isopropanol to obtain the fosfomycin levofosfomycin dextroamine salt, wherein the yield is 95.7%.
Example 5
At room temperature, 0.1mol of cis-propenyl phosphonic acid is dissolved in anhydrous isopropanol, then 0.12mol of (+) -alpha-phenylethylamine is slowly dripped, after the dripping is finished, the pH value of the system is adjusted to 5.5, the stirring is continued for 3min, then 0.3g of silver carbonate powder is added, 22.7g (0.2mol) of 30% hydrogen peroxide is slowly dripped, after the dripping is finished, the stirring is continued for 20min, the reaction is finished, then the system is heated to 60 ℃ within 3min, the hot filtering is carried out, the filtrate is cooled to 5 ℃ for crystallization, and then the crystal is washed by glacial isopropanol to obtain the fosfomycin levofosfomycin dextroamine salt, wherein the yield is 96.9%.
Finally, it should be noted that: it should be understood that the above examples are only for clearly illustrating the present invention and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications of the invention may be made without departing from the scope of the invention.
Claims (10)
1. The application of a silver catalyst in preparing an antibacterial drug intermediate fosfomycin levo-fosfomycin dextroamine salt is that the silver catalyst is preferably silver carbonate.
2. The use of a silver catalyst according to claim 1 for the preparation of the antibiotic intermediate fosfomycin levofosfomycin dextroamine salt, characterized in that it comprises the following steps: at room temperature, dissolving cis-propenyl phosphonic acid in an alcohol solvent, slowly dripping (+) -alpha-phenylethylamine, adjusting the pH of the system to 5.5-6 after dripping is finished, continuously stirring for 1-3 min, then adding a silver catalyst, continuously and slowly dripping hydrogen peroxide, continuously stirring for 10-30 min after finishing dripping, quickly heating the system to 50-55 ℃, filtering while hot, cooling the filtrate, crystallizing and washing to obtain the fosfomycin levofosfomycin dextroamine salt.
3. Use of a silver catalyst according to claim 2 in the preparation of fosfomycin levofosfomycin dextroamine salt as an antibacterial intermediate, said alcoholic solvent being selected from one or more of methanol, ethanol, n-propanol or isopropanol.
4. Use of the silver catalyst according to any one of claims 2 to 3 in preparation of an antibacterial drug intermediate fosfomycin levo-fosfomycin dextroamine salt, wherein the feeding ratio of the cis-propenyl phosphonic acid to the silver catalyst is 1mol: 1-5 g.
5. The use of the silver catalyst according to any one of claims 2 to 4 in the preparation of an antibacterial drug intermediate fosfomycin levo-phosphamide salt, wherein the hydrogen peroxide is selected from hydrogen peroxide with a concentration of 30%, and the molar amount of the hydrogen peroxide is 1.5 to 2 times that of cis-propenyl phosphonic acid.
6. Use of the silver catalyst according to any one of claims 2 to 5 for the preparation of the antibacterial intermediate fosfomycin levofosfomycin dextroamine salt, the solvent used for washing being an alcoholic solvent of ice.
7. Use of the silver catalyst according to claim 6 for preparing an antibacterial intermediate fosfomycin levofosfomycin dextroamine salt, wherein the alcohol solvent of ice is selected from one or more of ice methanol, ice ethanol, ice n-propanol or ice isopropanol.
8. The use of the silver catalyst according to any one of claims 1 to 7 for preparing an antibacterial drug intermediate fosfomycin levo-fosfomycin dextroamine salt, wherein the cooling of the reaction system means that the reaction system is cooled to 0-5 ℃.
9. Use of the silver catalyst according to any one of claims 2 to 8 for preparing an antibacterial intermediate fosfomycin levofosfomycin dextroamine salt, wherein the rapid heating time to 50 to 55 ℃ is 1 to 3 min.
10. Use of the silver catalyst according to any one of claims 2 to 9 for preparing an antibacterial intermediate fosfomycin levofosfomycin dextroamine salt, wherein the molar charge ratio of the cis-propenyl phosphonic acid to the (+) -alpha-phenylethylamine is 1: 1-1.5, preferably 1: 1.1-1.5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011426536.1A CN112409410A (en) | 2020-12-09 | 2020-12-09 | Application of silver catalyst in preparation of antibacterial intermediate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011426536.1A CN112409410A (en) | 2020-12-09 | 2020-12-09 | Application of silver catalyst in preparation of antibacterial intermediate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112409410A true CN112409410A (en) | 2021-02-26 |
Family
ID=74776739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011426536.1A Pending CN112409410A (en) | 2020-12-09 | 2020-12-09 | Application of silver catalyst in preparation of antibacterial intermediate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112409410A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113336791A (en) * | 2021-05-19 | 2021-09-03 | 千辉药业（安徽）有限责任公司 | Production method of fosfomycin calcium bulk drug |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3733356A (en) * | 1969-12-29 | 1973-05-15 | Merck & Co Inc | Process for the preparation of cis-1-propenylphosphonic acid |
| CN1385435A (en) * | 2002-06-07 | 2002-12-18 | 清华大学 | Process for synthesizing fosfomycin using cis-propenyl phosphonic acid as raw material |
| CN103113408A (en) * | 2012-12-10 | 2013-05-22 | 安徽赛诺医药化工有限公司 | Novel method for preparing fosfomycin phenylethylamine |
| CN112442084A (en) * | 2020-12-03 | 2021-03-05 | 商河探荣新技术开发中心 | Preparation method of antibacterial drug intermediate |
-
2020
- 2020-12-09 CN CN202011426536.1A patent/CN112409410A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3733356A (en) * | 1969-12-29 | 1973-05-15 | Merck & Co Inc | Process for the preparation of cis-1-propenylphosphonic acid |
| CN1385435A (en) * | 2002-06-07 | 2002-12-18 | 清华大学 | Process for synthesizing fosfomycin using cis-propenyl phosphonic acid as raw material |
| CN103113408A (en) * | 2012-12-10 | 2013-05-22 | 安徽赛诺医药化工有限公司 | Novel method for preparing fosfomycin phenylethylamine |
| CN112442084A (en) * | 2020-12-03 | 2021-03-05 | 商河探荣新技术开发中心 | Preparation method of antibacterial drug intermediate |
Non-Patent Citations (1)
| Title |
|---|
| 严晶等: ""磷霉素合成的研究进展"", 《华西药学杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113336791A (en) * | 2021-05-19 | 2021-09-03 | 千辉药业（安徽）有限责任公司 | Production method of fosfomycin calcium bulk drug |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112442084B (en) | Preparation method of antibacterial drug intermediate | |
| CN100497349C (en) | Improved Biapenem preparation method | |
| JPH01319463A (en) | 7-substituted quinolone and naphrhylicone- carboxylic acid derivative | |
| CN112409410A (en) | Application of silver catalyst in preparation of antibacterial intermediate | |
| CN114920691B (en) | Preparation method of N- (2-hydroxyethyl) nicotinamide and preparation method of nicorandil | |
| GB2138806A (en) | Benzoquinolizine carboxylic acid anti-bacterial compounds | |
| JPS6025998A (en) | 9-deoxo-9a-alkyl-9a-aza-9a-homoerythromycin a derivative | |
| CN112876436B (en) | Method for preparing furan ammonium salt with high selectivity | |
| TW530059B (en) | Improved process for antiparasitic agent | |
| CN104341435B (en) | The process for purification of ceftriaxone sodium | |
| CN107880083A (en) | A kind of process for purification of clindamycin phosphate | |
| CN108084161A (en) | The preparation method of De Lasha stars and its intermediate | |
| CN112321636B (en) | Preparation method of antibiotic intermediate | |
| JPS60126284A (en) | Pyridonecarboxylic acid derivative and salt thereof | |
| CN114031607B (en) | Refining method of delafloxacin and intermediate thereof | |
| CN105198904A (en) | Preparing method for levofloxacin and ofloxacin | |
| CN109293631B (en) | Preparation method of 3-amino-N- (2, 6-dioxo-3-piperidyl) -phthalimide compound | |
| CN103113408A (en) | Novel method for preparing fosfomycin phenylethylamine | |
| JPS61268687A (en) | Sf-2370 substance derivative and production thereof | |
| CN112110974A (en) | Method for purifying medicinal cholesterol | |
| CN112480142B (en) | Preparation method of 9-defluorinated-9-methylpiperazine levofloxacin impurity | |
| CN109053623A (en) | A kind of novel processing step of 4- methyl-5-thiazole formaldehyde | |
| CN114671783B (en) | Preparation method of 4,4' -dinitro diphenyl urea | |
| CN114195761B (en) | Preparation method of high-purity sitafloxacin hydrate 3/2 | |
| CN112321731B (en) | Photoactivated tea sapogenin cellulose nano material and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210226 |